Acute MCL1 loss via homoharringtonine-mediated translational inhibition enables potent apoptotic synergy with BCLXL blockade
Cancer Letters · 2026-12 · 663 · 218895
DOI: 10.1016/j.canlet.2026.218895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Akira Ohtsu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan; Department of Medicine, B…. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Japan Society for the Promotion of Science, Japan Society for the Promotion of Science London.
Abstract (Originalsprache)
Antiapoptotic buffering in solid tumors is generally mediated by both BCLXL and MCL1, so that BH3 mimetic drugs targeting only one have limited efficacy. To identify agents that may sensitize tumors to BH3 mimetics targeting BCLXL, we screened prostate cancer cells against a panel of mitochondria-targeted drugs in combination with navitoclax, a BH3 mimetic targeting BCL2 and BCLXL. Homoharringtonine (HHT) in combination with navitoclax and as a single agent emerged as a potent inducer of apoptosis. HHT has been identified as an inhibitor of protein translation, and proteomic analysis showed broad suppression of translation-related pathways, while immunoblotting demonstrated rapid decreases in short-lived proteins, including MCL1. HHT dose response and time course studies showed marked declines in MCL1 within 2 h that were associated with apoptosis in response to BCLXL inhibition with navitoclax or A1331852. Further cell viability assays showed synergy between HHT and BCLXL inhibitors in multiple prostate, lung, and colorectal cancer cell lines. HHT monotherapy in vivo caused tumor regression in two prostate cancer xenograft models. Analysis of tumor tissue taken at 4 h after dosing showed decreases in MCL1 and MYC, indicating that HHT levels obtainable in vivo are adequate to deplete short-lived proteins and potentially sensitize to BH3 mimetics targeting BCLXL. These findings support further exploration of HHT as a single agent in solid tumors and establish a rationale for investigating safer, tumor-selective approaches to combine HHT-mediated translational inhibition with BCLXL targeting.
Autor:innen und Institutionen
- Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, M…
- Department of Urology, Gunma University Graduate School of Medicine, 3-9-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
- Division of Pathology, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK.
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, 02115, USA; Harvard Medical School, Boston, MA, USA; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry a…
Förderung
- NCI NIH HHS
- Japan Society for the Promotion of Science
- Japan Society for the Promotion of Science London
- Yamaguchi Endocrine Research Foundation
- National Institutes of Health National Cancer Institute
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
Zitieren
APA
Ohtsu, A., Sawada, T., Poluben, L., Onose, M., Oyama, H., Katayama, A., Xie, F., Ersoy-Fazlioglu, B., Jiménez-Vacas, J. M., Otani, Y., Miyazawa, Y., Sekine, Y., Maeno, Y., Shimizu, T., Oda, T., Chen, S., Voznesensky, O., Yuan, X., Cecchi, L. G., …, & Arai, S. (2026). Acute MCL1 loss via homoharringtonine-mediated translational inhibition enables potent apoptotic synergy with BCLXL blockade. Cancer Letters, 663, 218895. https://doi.org/10.1016/j.canlet.2026.218895
Vancouver
Ohtsu A, Sawada T, Poluben L, Onose M, Oyama H, Katayama A, et al. Acute MCL1 loss via homoharringtonine-mediated translational inhibition enables potent apoptotic synergy with BCLXL blockade. Cancer Letters. 2026;663:218895. doi:10.1016/j.canlet.2026.218895
BibTeX
@article{Ohtsu2026,
author = {Ohtsu, Akira and Sawada, Tatsuhiro and Poluben, Larysa and Onose, Mai and Oyama, Hayumi and Katayama, Ayaka and Xie, Fang and Ersoy-Fazlioglu, Betul and Jiménez-Vacas, Juan M and Otani, Yusuke and Miyazawa, Yoshiyuki and Sekine, Yoshitaka and Maeno, Yuta and Shimizu, Takanori and Oda, Tsukasa and Chen, Shaoyong and Voznesensky, Olga and Yuan, Xin and Cecchi, Luigi Giovanni and Cerulli, Robert A and Izumi, Motohiro and Kobayashi, Ikei S and Tanaka, Atsushi and Sasaki, Nobuo and Kobayashi, Susumu S and Suzuki, Kazuhiro and Balk, Steven P and Arai, Seiji},
title = {Acute MCL1 loss via homoharringtonine-mediated translational inhibition enables potent apoptotic synergy with BCLXL blockade},
journal = {Cancer Letters},
year = {2026},
volume = {663},
pages = {218895},
doi = {10.1016/j.canlet.2026.218895}
}
EUVIMED